3,4-methylenedioxycinnamic acid bornyl ester

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 3,4-methylenedioxycinnamic acid bornyl ester
• 英文别名: (E)-(1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl 3-(benzo[d][1,3]dioxol-5-yl))acrylate；(E)-(1R,2S,4R)-1,7,7-Trimethylbicyclo[2.2.1]heptan-2-yl 3-(benzo[d][1,3]dioxol-5-yl)acrylate；(1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl) (E)-3-(1,3-benzodioxol-5-yl)prop-2-enoate
• 化学式: C₂₀H₂₄O₄
• 分子量: 328.408
• InChiKey: PYUDOIXLMHGZJD-FNORWQNLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  莰烯 、 3,4-(亚甲二氧)肉桂酸 在 三氟化硼乙醚 作用下， 以 二氯甲烷 为溶剂， 以79 %的产率得到3,4-methylenedioxycinnamic acid bornyl ester
  参考文献：
  名称：

  莰烯选择性转化为异龙脑衍生物的温和合成方法

  摘要：

  发表于《国际有机制备和程序：有机合成新期刊》（第 56 卷，第 1 期，2024 年）

  DOI：

  10.1080/00304948.2023.2219198

文献信息

• Kava derived therapeutic compounds and methods of use thereof
  申请人：KUALITY HERBCEUTICS LLC

  公开号：US10624943B2

  公开（公告）日：2020-04-21

  Certain embodiments of the invention provide a composition comprising at least two compounds selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the composition is substantially free of flavokawain B. Certain embodiments of the invention also provide a method for treating or preventing cancer in a mammal (e.g., a human) in need of such treatment comprising, administering to the mammal a carrier and a compound selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the compound is substantially free of other kava extract components.

  本发明的某些实施方案提供了一种组合物，该组合物包含至少两种选自由二氢麦角苷、甲基麦角苷、二氢卡瓦胡椒素、卡瓦胡椒素、去甲氧基麦角苷和11-甲氧基麦角苷组成的组的化合物，其中该组合物基本上不含黄卡瓦胡椒素B、向哺乳动物施用载体和选自由二氢甲基芪烷素、甲基芪烷素、二氢卡瓦胡椒素、卡瓦胡椒素、去甲氧基卡瓦胡椒素和 11-甲氧基卡瓦胡椒素组成的组的化合物，其中该化合物基本上不含其他卡瓦提取物成分。
• KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
  申请人：XING Chengguo

  公开号：US20160279184A1

  公开（公告）日：2016-09-29

  Certain embodiments of the invention provide a composition comprising at least two compounds selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the composition is substantially free of flavokawain B. Certain embodiments of the invention also provide a method for treating or preventing cancer in a mammal (e.g., a human) in need of such treatment comprising, administering to the mammal a carrier and a compound selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the compound is substantially free of other kava extract components.
• [EN] KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES ISSUS DU KAVA ET LEURS PROCÉDÉS D'UTILISATION
  申请人：KUALITY HERBCEUTICS LLC

  公开号：WO2015070226A1

  公开（公告）日：2015-05-14

  Certain embodiments of the invention provide a composition comprising at least two compounds selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the composition is substantially free of flavokawain B. Certain embodiments of the invention also provide a method for treating or preventing cancer in a mammal (e.g., a human) in need of such treatment comprising, administering to the mammal a carrier and a compound selected from the group consisting of dihydromethysticin, methysticin, dihydrokavain, kavain, desmethoxyyangonin and 11-methoxyyangonin, wherein the compound is substantially free of other kava extract components.
• A Mild Synthetic Method for Selective Conversion of Camphene to Isoborneol Derivatives
  作者：Sujata V. Bhat、Manisha O. Gupta、Kedar R. Vaze

  DOI：10.1080/00304948.2023.2219198

  日期：2024.1.2

  Published in Organic Preparations and Procedures International: The New Journal for Organic Synthesis (Vol. 56, No. 1, 2024)

  发表于《国际有机制备和程序：有机合成新期刊》（第 56 卷，第 1 期，2024 年）